Subscribe
shutterstock_728430565_casimiropt
casimiropt / Shutterstock.com
15 May 2019Americas

Clean sweep for AbbVie in Humira litigation

Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira (adalimumab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Abbvie faces multiple Humira antitrust suits
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
Big Pharma
Boehringer teams up with Gubra to develop second obesity treatment
30 May 2019   German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Abbvie faces multiple Humira antitrust suits
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
Big Pharma
Boehringer teams up with Gubra to develop second obesity treatment
30 May 2019   German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.

More on this story

Americas
Abbvie faces multiple Humira antitrust suits
4 April 2019   AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.
Americas
AbbVie and Pfizer in Humira licensing deal
3 December 2018   AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
Big Pharma
Boehringer teams up with Gubra to develop second obesity treatment
30 May 2019   German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?